Taking multiple blood pressure medications but still have high readings? Aldosterone excess might be sabotaging your ...

Lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced 24-hour systolic blood pressure in individuals with uncontrolled and treatment-resistant hypertension, according to ...

A novel treatment, an aldosterone synthase inhibitor, safely and consistently lowered blood pressure in individuals with ...

New drug lorundrostat shows promising results in lowering blood pressure for patients with resistant hypertension.

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Mineralys Therapeutics, Inc.'s lorundrostat shows promise for treating aldosterone-driven hypertension with FDA approval by ...

Have you ever wondered how people survive the blistering, almost surreal heat of the world’s deserts? Picture yourself ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Investigating genetic variations in the vitamin D receptor (VDR) gene has revealed inconsistent associations with ...

Spironolactone does not reduce the rate of cardiovascular death or heart failure in patients undergoing maintenance dialysis.

Song, Z. and Zhong, W. (2025) Research Advances in Subtype Classification and Diagnosis of Primary Aldosteronism. Journal of Biosciences and Medicines, 13, 1-11. doi: 10.4236/jbm.2025.136001 .

Mineralys has reported outcomes from its pivotal randomised, placebo-controlled Phase III Launch-HTN trial assessing ...